Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

294.53 +4.63 (+1.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
47 48 Next >
Stock Market Rally Hits 2023 Highs As Big Techs Lead; Tesla, Walmart, On Holding In Focus: Weekly Review
Chips, software and AI plays were strong. But leadership remains narrow. 
Via Investor's Business Daily
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
Despite worries about FTC scrutiny, Pfizer remains optimistic about its planned Seagen acquisition, issuing $31 billion in bonds to finance the deal. 
Via MarketBeat
Topics Bonds
Exposures Debt Markets
3 Safe Dividend Stocks to Beat Inflation
Look for businesses that thrive in any economic environment. 
Via The Motley Fool
The FTC, Amgen, And Horizon: A New Hurdle For Biotech Deal Making Or Regulatory Overreach?
The FTC suit against Amgen appears to be a clear case of regulatory overreach but what this ultimately means will take time to fully develop. 
Via Talk Markets
Why Horizon Therapeutics Stock Is Crashing Today
The FTC is reportedly gearing up to block the drugmaker's takeover by Amgen. 
Via The Motley Fool
Looking Into Amgen's Recent Short Interest
Via Benzinga
Analyst Ratings for Amgen
Via Benzinga
What Does Amgen's Debt Look Like?
Via Benzinga
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Exposures Product Safety
TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients
TScan Therapeutics Inc (NASDAQ: TCRX) announced a poster presentation highlighting preliminary data from the Phase 1 umbrella clinical trial evaluating TSC-100 and TSC-101 targeting minor... 
Via Benzinga
FDA Signals Support For Pfizer's Maternal RSV Shot Ahead Of Adcomm, Pfizer Raises $31B In Debt To Fund Seagen Deal
Pfizer Inc (NYSE: PFE) plans to raise $31 billion from a debt offering to finance its proposed acquisition of Seagen Inc (NASDAQ: SGEN)  
Via Benzinga
FTC Seeks to Block Amgen's Acquisition of Horizon Therapeutics: What's Next for Both Stocks?
Don't bank on the FTC winning in its attempt to stop Amgen's buyout of Horizon just yet. 
Via The Motley Fool
Is This Dow Jones Stock a Buy for Income Investors?
This pharmaceutical company is dedicated to maintaining its track record of innovation. 
Via The Motley Fool
Why These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today. 
Via The Motley Fool
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
In a rare move to block a large pharma deal, the U.S. 
Via Benzinga
Why These 2 Large-Cap Stocks Dropped 10%-Plus on Tuesday
Their declines weighed on the broader market. 
Via The Motley Fool
Former SVB CEO Blames Fed & Media Hype For Collapse, FTC Plans Lawsuit to Block Horizon Therapeutics $28B Takeover, Home Depot Lowers Annual Outlook: Today's Top Stories
Benzinga Former SVB Chief Blames Fed, Media Hype For Bank's Devastating Collapse 
Via Benzinga
HZNP Stock Alert: Why Is Horizon Therapeutics Plunging Today
Horizon Therapeutics (HZNP) stock is sinking after the FTC reportedly decided to sue to block its merger with Amgen (AMGN). 
Via InvestorPlace
Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover
Reports the FTC could block Amgen's takeover of Horizon reverberated across biotechs on Tuesday, with HZNP stock's crash leading the way. 
Via Investor's Business Daily
Amgen-Horizon Therapeutics Deal Regulatory Overhang: FTC Plans Lawsuit to Block $28B Takeover
The Federal Trade Commission is expected to file a lawsuit in a bid to block Amgen Inc's (NASDAQ: AMGN) $28 billion takeover of Horizon Therapeutics PLC (NASDAQ: HZNP). 
Via Benzinga
The Turnaround for Weight Watchers is Taking Shape
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares 
Via MarketBeat
S&amp;P 500 Futures Slip After Home Depot's Q1 Print: Analyst Says Retest Of October Lows Likely
Via Benzinga
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)
From The Law Offices of Frank R. Cruz
Via Business Wire
AMGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Amgen Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
NASDAQ:AMGN Investor Notice: Deadline on May 12, 2023 in Lawsuit Against Amgen Inc. Coming Up
San Diego, CA -- (SBWIRE) -- 05/10/2023 -- The Shareholders Foundation announced that a deadline is coming up on May 12, 2023 in the lawsuit filed for certain investors of Amgen Inc. (NASDAQ:AMGN). 
Via SBWire
Why Are TScan Therapeutics Shares Are Shooting Higher Today
Amgen Inc (NASDAQ: AMGN) and TScan Therapeutics Inc (NASDAQ: TCRX) announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recog 
Via Benzinga
TScan Therapeutics (NASDAQ: TCRX) and Amgen (NASDAQ: AMGN) Join Forces to Battle Crohn’s Disease
TScan Therapeutics, Inc. (NASDAQ: TCRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
Check Out 3 Health Care Stocks With Over 3% Dividend Yields From Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
From TScan Therapeutics, Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.